Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated ...

As of the latest trading close, GOSS, a Healthcare sector stock, is trading -44.61% below its 52-week high but remains 89.62% above its 52-week low. The Average True Range (ATR) (14 days) of 0.06 ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago. These figures are ...

Gossamer Bio ( (GOSS)) has released its Q3 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company ...

The company, known for creating the Barbie dolls, has ensured the are taking “immediate action” to fix the mistake ...

As you might know, Gossamer Bio, Inc. (NASDAQ:GOSS) just kicked off its latest quarterly results with some very strong numbers. Results clearly exceeded expectations, with a substantial revenue beat ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Stock analysts at Barrington Research boosted their FY2024 earnings estimates for VIZIO in a research report issued on ...

Stephan Goss is president and CEO of Zeeto, a rapidly growing innovator of ad technology. Since he started Zeeto in 2010 at the age of 22 the company has grown from two employees to more than 60.

SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Thursday reported a loss of $30.8 million in its third quarter. The San Diego-based company said it had a loss of 14 cents per share.